Literature DB >> 11983450

Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines.

Ichiro Yasuda1, Yoshimune Shiratori, Seiji Adachi, Akihiro Obora, Masao Takemura, Masataka Okuno, Yoshihiro Shidoji, Mitsuru Seishima, Yasutoshi Muto, Hisataka Moriwaki.   

Abstract

BACKGROUND/AIMS: Acyclic retinoid (AR; all trans-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) prevented hepatocarcinogenesis in animal models and in a randomized clinical trial by eradicating premalignant and latent malignant clones of transformed cells from the liver. We investigated the possible mechanism of this clonal deletion at the cellular level.
METHODS: Human hepatoma-derived cell lines, PLC/PRF/5, HuH-7, and JHH-7, were treated in vitro with AR. Secretion of albumin and that of lectin-reactive isoform of alpha-fetoprotein (AFP-L3) were measured as markers of differentiation and dedifferentiation of the cells, respectively. Telomerase reverse transcriptase (TERT) mRNA expression and telomerase activity were measured by reverse transcriptase polymerase chain reaction (RT-PCR) and stretch PCR assay, respectively. Caspase activities were measured by colorimetric protease assay. Mitochondrial membrane permeability transition was examined by Rhodamine staining.
RESULTS: Production of albumin was recovered while that of AFP-L3 was reduced after exposure of the cells to 10 microM AR for 2 days. This differentiation was maintained for another 2 days without retinoid. In parallel, both TERT mRNA expression and telomerase activity were down-regulated. The cells subsequently died due to apoptosis after 4-6 experimental days. Serial increases in mitochondrial membrane permeability and caspase-9 and -3 activities induced apoptosis.
CONCLUSIONS: AR first induces differentiation and reduces telomerase activity. Subsequent apoptosis may contribute to the eradication of the clone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983450     DOI: 10.1016/s0168-8278(02)00044-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

1.  Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2.

Authors:  Junichi Kitagawa; Takeshi Hara; Hisashi Tsurumi; Soranobu Ninomiya; Kengo Ogawa; Seiji Adachi; Nobuhiro Kanemura; Senji Kasahara; Masahito Shimizu; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-31       Impact factor: 4.553

2.  Recombinant FVII in orthotopic liver transplantation (OLT): a preliminary single centre experience.

Authors:  Andrea De Gasperi; Francesco Baudo; Luciano De Carlis
Journal:  Intensive Care Med       Date:  2004-12-09       Impact factor: 17.440

Review 3.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Shun-Yuan Jiang; Jung-Mao Chou; Fur-Jiang Leu; Yu-Yen Hsu; Yu-Lung Shih; Jyh-Cherng Yu; Meei-Shyuan Lee; Rong-Yaun Shyu
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

5.  Down-regulation of retinol binding protein 5 is associated with aggressive tumor features in hepatocellular carcinoma.

Authors:  Jenny C Y Ho; Siu Tim Cheung; Wing Sem Poon; Yuk Ting Lee; Irene O L Ng; Sheung Tat Fan
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-12       Impact factor: 4.553

6.  A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.

Authors:  Kimberly B Higginbotham; Richard Lozano; Thomas Brown; Yehuda Z Patt; Takashi Arima; James L Abbruzzese; Melanie B Thomas
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-27       Impact factor: 4.553

7.  Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.

Authors:  Masahito Shimizu; Yohei Shirakami; Kenji Imai; Koji Takai; Hisataka Moriwaki
Journal:  J Carcinog       Date:  2012-08-30

8.  Acyclic retinoid induces differentiation and apoptosis of murine hepatic stem cells.

Authors:  Hong-Bin Guan; Yun-Zhong Nie; Yun-Wen Zheng; Kazuya Takiguchi; Hong-Wei Yu; Ran-Ran Zhang; Bin Li; Tomonori Tsuchida; Hideki Taniguchi
Journal:  Stem Cell Res Ther       Date:  2015-03-26       Impact factor: 6.832

9.  Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma.

Authors:  Masao Honda; Taro Yamashita; Tatsuya Yamashita; Kuniaki Arai; Yoshio Sakai; Akito Sakai; Mikiko Nakamura; Eishiro Mizukoshi; Shuichi Kaneko
Journal:  BMC Cancer       Date:  2013-04-15       Impact factor: 4.430

10.  Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study.

Authors:  Kiwamu Okita; Namiki Izumi; Osamu Matsui; Katsuaki Tanaka; Shuichi Kaneko; Hisataka Moriwaki; Kenji Ikeda; Yukio Osaki; Kazushi Numata; Kohei Nakachi; Norihiro Kokudo; Kazuho Imanaka; Shuhei Nishiguchi; Takuji Okusaka; Yoichi Nishigaki; Susumu Shiomi; Masatoshi Kudo; Kenichi Ido; Yoshiyasu Karino; Norio Hayashi; Yasuo Ohashi; Masatoshi Makuuchi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2014-04-13       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.